--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-070946" form_type: "8-K" ticker: "RNLXY" cik: "0001811115" company_name: "Renalytix plc" filed_at: "2023-12-18T23:59:59+00:00" generated_at: "2026-06-07T11:24:56.002529+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.25 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Renalytix annual meeting Dec 15: all proposals pass; ~41% of shares voted ## Summary - All 10 proposals passed at AGM on Dec 15, including adoption of FY2023 accounts, director re-appointments, and auditor ratifications. - Approximately 41.27% of shares (40.2 million ordinary shares) were represented at the meeting. - Directors authorized to allot shares up to aggregate nominal value of £85,251.39 and sell treasury shares. - Market purchase authority granted for buybacks on London Stock Exchange. - New articles of association adopted. ## SEC filing metadata - accession: 0000950170-23-070946 - form_type: 8-K - ticker: RNLXY - cik: 0001811115 - company_name: Renalytix plc - filed_at: 2023-12-18T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.25 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/rnlx-20231215.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-070946 - JSON: https://secwatch.observer/filing/0000950170-23-070946.json - Plain text: https://secwatch.observer/filing/0000950170-23-070946.txt ## Key facts - Shareholder Votes Renalytix plc shareholders approved To approve the Directors’ Remuneration Report set out on pages 38 to 54 (inclusive) of the 2023 U.K. Annual Report. at the 2023-12-15 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 2 – To approve the Directors’ Remuneration Report set out on pages 38 to 54 (inclusive) of the 2023 U.K. Annual Report. For Against Vote Withheld/Abstain 39,959,034 226,856 24,973 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To authorise the Directors of the Company to determine the auditors’ remuneration for the fiscal year ending June 30, 2024. at the 2023-12-15 meeting. - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 7 – To authorise the Directors of the Company to determine the auditors’ remuneration for the fiscal year ending June 30, 2024. For Against Vote Withheld/Abstain 40,105,519 77,729 27,615 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To re-appoint Catherine Coste as a Director of the Company. at the 2023-12-15 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 3 – To re-appoint Catherine Coste as a Director of the Company. For Against Vote Withheld/Abstain 39,058,428 1,086,363 66,072 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To authorise the Directors of the Company to (i) allot shares or grant rights to subscribe for, or convert any security into, shares up to a maximum aggregate nominal amount of £85,251.39 and (ii) allot further equity securities up to an aggregate nominal amount of £81,191.80 in connection with a pr at the 2023-12-15 meeting. - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 8 – To authorise the Directors of the Company to (i) allot shares or grant rights to subscribe for, or convert any security into, shares up to a maximum aggregate nominal amount of £85,251.39 and (ii) allot further equity securities up to an aggregate nominal amount of £81,191.80 in connection with a pre-emptive offer in favour of shareholders. For Against Vote Withheld/Abstain 38,484,392 1,697,234 29,237 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To re-appoint Messrs PKF Littlejohn LLP as auditors to act as such until the conclusion of the next annual general meeting of the Company. at the 2023-12-15 meeting. - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 6 – To re-appoint Messrs PKF Littlejohn LLP as auditors to act as such until the conclusion of the next annual general meeting of the Company. For Against Vote Withheld/Abstain 40,142,582 37,614 30,667 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved Subject to and conditional upon the passing of Proposal 8 above, to authorise the Directors of the Company to allot equity securities for cash pursuant to the authority conferred by Proposal 8 above and/or sell treasury shares in connection with a pre-emptive offer and otherwise up to a maximum aggr at the 2023-12-15 meeting. - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 9 – Subject to and conditional upon the passing of Proposal 8 above, to authorise the Directors of the Company to allot equity securities for cash pursuant to the authority conferred by Proposal 8 above and/or sell treasury shares in connection with a pre-emptive offer and otherwise up to a maximum aggregate nominal amount of £85,251.39 . For Against Vote Withheld/Abstain 38,467,804 1,710,946 32,113 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To adopt the draft articles of association produced to the AGM as the articles of association of the Company. at the 2023-12-15 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 11 – To adopt the draft articles of association produced to the AGM as the articles of association of the Company. For Against Vote Withheld/Abstain 40,059,859 104,681 46,323 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To ratify the selection of Ernst & Young LLP ("EY") as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. at the 2023-12-15 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 5 – To ratify the selection of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. For Against Vote Withheld/Abstain 39,266,710 910,387 33,766 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To receive and adopt the accounts for the year ended June 30, 2023 together with the reports of the Directors and the auditors thereon (the "2023 U.K. Annual Report"). at the 2023-12-15 meeting. - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 1 – To receive and adopt the accounts for the year ended June 30, 2023 together with the reports of the Directors and the auditors thereon (the “2023 U.K. Annual Report”). For Against Vote Withheld/Abstain 40,118,702 24,743 67,418 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm - Shareholder Votes Renalytix plc shareholders approved To generally and unconditionally authorise the Company to make one or more market purchases on the London Stock Exchange of ordinary shares of £0.0025 each in the capital of the Company on such terms and in such manner as the Directors may from time to time decide. at the 2023-12-15 meeting. - Outcome: passed - Meeting: 2023-12-15 source text: Proposal 10 – To generally and unconditionally authorise the Company to make one or more market purchases on the London Stock Exchange of ordinary shares of £0.0025 each in the capital of the Company on such terms and in such manner as the Directors may from time to time decide. For Against Vote Withheld/Abstain 39,597,340 51,284 562,239 evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023070946/0000950170-23-070946-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.